Zacks: Analysts Anticipate Mirum Pharmaceuticals (NASDAQ:MIRM) to Post -$0.85 EPS

Brokerages predict that Mirum Pharmaceuticals (NASDAQ:MIRM) will post ($0.85) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Mirum Pharmaceuticals’ earnings. The highest EPS estimate is ($0.83) and the lowest is ($0.86). The business is expected to report its next earnings results on Wednesday, February 5th.

According to Zacks, analysts expect that Mirum Pharmaceuticals will report full-year earnings of ($4.84) per share for the current financial year. For the next fiscal year, analysts anticipate that the business will report earnings of ($3.36) per share, with EPS estimates ranging from ($3.49) to ($3.22). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Mirum Pharmaceuticals.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.84) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.59) by ($0.25).

Separately, Zacks Investment Research raised Mirum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $22.25.

Shares of NASDAQ:MIRM opened at $9.57 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.85 and a current ratio of 11.85. The stock’s 50-day simple moving average is $7.55. Mirum Pharmaceuticals has a 1 year low of $6.51 and a 1 year high of $15.50.

Several institutional investors have recently bought and sold shares of the company. California State Teachers Retirement System acquired a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter valued at about $42,000. State Street Corp purchased a new position in Mirum Pharmaceuticals in the 3rd quarter worth about $197,000. Dean Capital Investments Management LLC purchased a new position in Mirum Pharmaceuticals in the 3rd quarter worth about $457,000. Finally, Millennium Management LLC bought a new position in Mirum Pharmaceuticals during the 3rd quarter valued at about $1,261,000. 71.72% of the stock is owned by institutional investors and hedge funds.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).

Further Reading: When can a hold rating present a buying opportunity?

Get a free copy of the Zacks research report on Mirum Pharmaceuticals (MIRM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit